From: Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
 | INH + Rifampicin | INH + Rifampicin + ethambutol |
---|---|---|
Age in years, median, (range) | 25 (16–75) | 25 (16–76) |
Sex, n/N (%) | ||
 Male | 46/103 (44.6) | 48/101 (47.5) |
 Female | 57/103 (55.3) | 53/101 (52.4) |
History of contact with TB, n/N (%) | ||
 a Recent | 21/103 (20.3) | 20/101 (19.8) |
 b Previous | 17/103 (16.5) | 22/101 (21.7) |
 No history of contact | 65/103 (63.1) | 59/101 (58.4) |
Prevalence of HIV | 0/103 | 0/103 |
Smoker n/N (%) | 4/103 (3.8) | 10/101 (9.9) |
Prevalence of diabetes n/N (%) | 8/103 (7.7) | 3/101 (2.9) |
cBacillary load before treatment n/N (%) | ||
 scanty | 10/103 (9.7) | 10/101 (9.9) |
  + 1 | 57/103 (55.4) | 60/101 (59.4) |
  + 2 | 25/103 (24.2) | 12/101 (11.9) |
  + 3 | 11/103 (10.7) | 19/101 (18.8) |
Chest X-ray n/N (%) | ||
 Cavitary lesions | 3/7 (42.9) | 4/7 (57.1) |
 Non-cavitary infiltrates | 49/95 (51.6) | 46/95 (48.4) |
 Not available | 50/102 (49.1) | 52/102 (50.9) |